Systemic lupus erythematosus (SLE) is the form of the disease that most people are referring to when they say "lupus." The word "systemic" means the disease can affect many parts of the body. The symptoms of SLE may be mild or serious. Although SLE usually first affects people between the ages of 15 and 45 years, it can occur in childhood or later in life as well.
SLE is a heterogeneous disease, which can cause many different manifestations and symptoms, and traditionally did not have many treatment options.
Rheumatoid arthritis (RA) is an autoimmune disease characterized by inflammation that leads to pain, joint damage, and disability, which affects approximately 18 million people worldwide.
New research at ACR Convergence 2023, the American College of Rheumatology's annual meeting, demonstrates that CAR-T cell therapy could lead to sustained suppression of autoantibodies in treatment-resistant lupus while maintaining a robust response to vaccines.
Leaders of a project to develop and implement equitable new quality measures for lupus care by the end of the decade will present their work at ACR Convergence 2023, the American College of Rheumatology's annual meeting.
New research at ACR Convergence 2023, the American College of Rheumatology's (ACR) annual meeting, describes a link between positive antiphospholipid antibodies and an increased risk of future cardiovascular disease in patients with systemic lupus erythematosus (SLE).
The research paper explores the multifaceted role of the IL-17 family in immune response, covering everything from infection control to pathological conditions like autoimmune diseases and cancer. Future therapies may exploit IL-17's unique signaling pathways to offer more targeted and cost-effective treatments.
Artificial intelligence, AI, which finds patterns in complex biological data could eventually contribute to the development of individually tailored healthcare.
SARS-CoV-2 infection may elevate risk for certain autoimmune disorders, suggests study. Regular post-COVID monitoring needed to detect and manage potential autoimmune consequences.
Researchers evaluated new-onset autoimmune disease risk among individuals with new-onset psoriatic illness.
Researchers at Stanford University School of Medicine, Yale University School of Medicine, and the Hospital for Special Surgery Research Institute have uncovered new details about how the immune system prevents the production of antibodies that can recognize and damage the body's own, healthy tissues.
In the largest study to date exploring the relationship between severe psoriasis and coronary microvascular dysfunction, researchers have found further evidence that patients with severe psoriasis are at higher cardiovascular risk.
A groundbreaking discovery has been made by Professor Hyug Moo Kwon and his research team in the Department of Biological Sciences at UNIST, in collaboration with Professor Jaeseok Yang from Yonsei University.
In the ever-perilous autoimmune disease world of systemic lupus erythematosus (SLE or lupus), up to 60% of adult patients and 80% of children will develop lupus nephritis (LN), and up to half of those will move on to end-stage renal disease.
Researchers across Europe have delved into the DNA methylation patterns in CD4+ T-cells of psoriasis and psoriatic arthritis (PsA) patients, unveiling potential new biomarkers for these conditions. Their study suggests that these unique profiles could serve as both diagnostic and prognostic tools, although further validation is needed for real-world clinical application.
Scientists at CeMM, Max Perutz Labs, and St. Anna Children's Cancer Research Institute in Vienna have achieved a significant advancement in the research of rare immune system disorders.
Researchers trained machine learning (ML) models to analyze RNA molecular signatures in patients’ blood.
Researchers described the preclinical profile of JT002, a novel and orally bioavailable small molecule inhibitor of the NLRP3 inflammasome.
COVID-19 can increase the risk of various autoimmune diseases; however, this risk appears to be mitigated by vaccination against COVID-19.
Chandra Mohan, Hugh Roy and Lillie Cranz Cullen Endowed Professor of biomedical engineering, is reporting the first use of the powerful imaging mass cytometry (IMC) to examine the kidneys of patients with lupus (systemic lupus erythematosus), an autoimmune disease that can affect multiple organs and become fatal, and to diagnose lupus nephritis (LN) in those patients.
Researchers explore the role of self-extracellular nucleic acids in diseases like stroke, multiple sclerosis, Alzheimer’s disease, and Parkinson’s disease.